IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.27

Change

-0.78 (-1.10)%

Market Cap

N/A

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.61 (-1.09%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

-0.63 (-0.91%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-1.41 (-1.33%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

+0.22 (+0.26%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.28 (-1.28%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.43 (+1.43%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.14 (+0.15%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.11 (-0.41%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.13 (+0.21%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.36 (+1.88%)

USD 6.67M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.92% 100% F 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.92% 100% F 86% B+
Trailing 12 Months  
Capital Gain 3.93% 86% B+ 62% D
Dividend Return 1.37% 88% B+ 24% F
Total Return 5.31% 90% A- 54% F
Trailing 5 Years  
Capital Gain 52.10% 62% D 56% F
Dividend Return 10.24% 95% A 22% F
Total Return 62.34% 71% C- 50% F
Average Annual (5 Year Horizon)  
Capital Gain 3.92% 48% F 47% F
Dividend Return 5.31% 57% F 44% F
Total Return 1.40% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 15.23% 71% C- 66% D+
Risk Adjusted Return 34.87% 67% D+ 49% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike